Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Treatment Results of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusionopen access

Authors
Choi, Yu-JinChoi, Young JeCho, Yong WunYoo, Woong-SunChung, In Young
Issue Date
Sep-2021
Publisher
대한안과학회
Keywords
Bevacizumab; Branch retinal vein occlusion; Macular edema; Three-monthly regimen
Citation
대한안과학회지, v.62, no.9, pp 1207 - 1217
Pages
11
Indexed
SCOPUS
ESCI
KCI
Journal Title
대한안과학회지
Volume
62
Number
9
Start Page
1207
End Page
1217
URI
https://scholarworks.gnu.ac.kr/handle/sw.gnu/3299
DOI
10.3341/jkos.2021.62.9.1207
ISSN
0378-6471
2092-9374
Abstract
Purpose: To evaluate the results of treatment according to the method of intravitreal injection of bevacizumab for macular edema due to branch retinal vein occlusion (BRVO). Methods: The clinical records of macular edema patients were analyzed retrospectively for a total of 62 eyes of 62 patients who were injected with bevacizumab into the vitreous as the first treatment for BRVO. Best-corrected visual acuity (BCVA), the findings of spectral-domain optical coherence tomography before and after injection, and prognosis-related factors were evaluated for 21 eyes that received the initial three monthly loading treatments and the 41 eyes that did not. Results: Significant improvement in BCVA was observed in the group having received the initial three injections compared with the group who did not receive the injections at 3, 6, and 12 months (p = 0.025, p = 0.019, and p = 0.008, respectively). The central macular thickness (CMT) showed greater improvement in the initial three injections group than the group without at 6 months (p = 0.034). Multivariate regression showed that the duration from the onset, the three loadings, BCVA, disorganization of the retinal inner layer (DRIL), and choroidal thickness were predictors related to visual gain (p = 0.044, p = 0.047, p = 0.004, p = 0.045, and p = 0.034, respectively). Age, three loadings, BCVA, and DRIL were predictors related to final visual acuity ( p = 0.045, p = 0.046, p = 0.002, and p = 0.034, respectively). Duration from the onset, CMT, and choroidal thickness were predictors related to CMT improvement (p = 0.042, p = 0.009, and p = 0.015, respectively). Conclusions: In macular edema of BRVO, the initial three monthly intravitreal injections of bevacizumab provided superior treatment outcomes regarding short-term functional and anatomical improvements and long-term functional improvement, compared with methods that did not treat with the initial three monthly injections.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medicine > Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Chung, In Young photo

Chung, In Young
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE